FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Biblioteca de Stacks

Hair Growth Stack

Skin & Hairintermediate

78

síntesis

78
Share
Péptidos

3

Promedio Diario mcg

3,250

Nivel

intermediate

Añadido

May 17, 2026

Visión General

The Hair Growth Stack combines three regenerative peptides that target different aspects of hair follicle biology to promote hair density, thickness, and growth cycle optimization. GHK-Cu is the primary driver of this stack''s hair-specific effects. The copper-binding tripeptide has been shown to increase hair follicle size, stimulate proliferation of follicular keratinocytes, and extend the anagen (active growth) phase of the hair cycle. Studies demonstrate that GHK-Cu promotes expression of growth factors specific to the dermal papilla cells that control hair follicle activity, including FGF-7, VEGF, and Wnt signaling pathway components. Topical application allows direct delivery to the scalp, though subcutaneous injection provides systemic support for body-wide follicle health. BPC-157 contributes to hair restoration through its angiogenic properties — hair follicles are among the most metabolically active structures in the body and require robust blood supply. In androgenetic alopecia, miniaturization of follicles correlates with reduced perifollicular vascularity. BPC-157''s promotion of new blood vessel formation around follicles restores the nutrient and oxygen delivery needed for full-size hair production. Additionally, its anti-inflammatory effects may help resolve the chronic perifollicular inflammation (micro-inflammation) now recognized as a contributor to pattern hair loss. TB-500 provides systemic tissue remodeling support through its actin-polymerization and cell migration effects. Hair follicle cycling involves extensive tissue remodeling — the follicle partially destructs during catagen, then regenerates from stem cells during the telogen-to-anagen transition. TB-500''s promotion of stem cell migration and tissue repair supports these regenerative processes. The three-peptide combination addresses follicular vascularity (BPC-157), direct follicle stimulation and matrix remodeling (GHK-Cu), and systemic tissue repair capacity (TB-500). Results typically require 3-6 months of consistent use, as hair growth cycles operate on timescales of months rather than weeks.

Protocolo de Dosis

GHK-Cu

Every day· topical/subcutaneous

Leer más sobre GHK-Cu →

500 mcg

por dosis

BPC-157

Every day· subcutaneous

Leer más sobre BPC-157 →

250 mcg

por dosis

TB-500

2x/week· subcutaneous

Leer más sobre TB-500 →

2,500 mcg

por dosis

Objetivos & Evidencia

Hair growthFollicle stimulationHair densityScalp vascularityAlopecia support
Nivel de evidencia:Estudios Animales

Advertencias

  • Hair-related applications of BPC-157 and TB-500 are off-label. GHK-Cu topical data is strongest for this indication.

Comments

Sign in to join the discussion

Aviso: Este stack es subido por la comunidad y solo tiene fines de investigación. Peptide Contacts no verifica la seguridad o eficacia de los stacks subidos. Siempre consulte a un profesional de la salud calificado antes de usar cualquier protocolo de péptidos.